News | May 26, 2022
Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
To be marketed by Strides Pharma Inc. in the US market
They will commercialize molnupiravir in the international markets
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company expects revenue growth of 10-15 per cent in the US
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Subscribe To Our Newsletter & Stay Updated
